Currently, epidermal growth factor receptor (EGFR)—tyrosine kinase inhibitors (TKIs) are the standard treatment for patients with locally advanced or metastatic NSCLC with EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.